China has passed the medical insurance directory admission negotiations to incorporate

According to the China National Medical Insurance Administration, since the establishment of the bureau, through the admission negotiations of the medical insurance directory, 26 rare medical drugs have been included in the medical insurance directory, with an average price reduction of more than 50%.

According to the surging news on Thursday (August 24), the State Medical Insurance Administration issued a National Medical Security Bureau on the first session of the 14th National Committee of the CPPCC No. 03136 (Medical and Health No. 270)Letter of proposal response.

Answering letter shows that in recent years, the level of rare medical treatment in China has increased significantly.The first is to optimize the admission procedure and timely incorporate the eligible rare medical medication in the medical insurance directory.

The second is to promote the medical insurance directory admission negotiations and improve rare medical medication.Since the establishment of the State Medical Insurance Bureau, a total of 26 rare medical drugs have been included in the medical insurance directory, with an average price reduction of more than 50%.The 75 rare medical drugs currently approved by other drugs are currently approved by China, and more than 50 species have been included in the medical insurance catalog.

Third, establish a sound "dual channel" mechanism for medical insurance negotiation drugs to improve the level of rare medical supply guarantee.The National Medical Insurance Bureau and the State Health and Health Commission have issued a notice of the guidance on establishing and improving the "dual channel" management mechanism of the national medical insurance negotiations on the management mechanism of the "dual passage" of the medical insurance negotiations on the normalization of national medical insurance negotiations to continue to do a good job of the implementation of negotiating drugs.There are two channels for pharmacies to meet the reasonable needs of negotiated drug supply guarantees and clinical adaptation.

Fourth, the multi -level medical security system of rare diseases is continuously improved, and the cost of medication costs for patients with rare diseases will be effectively reduced. By improving the comprehensive assistance mechanism of patients with high cost burden, actively introduce market forces to promote charity organizations and businessAll parties such as health insurance and medical mutual assistance participated in the protection of assistance and played a joint force.

Next, the China National Medical Insurance Bureau continues to improve the medical insurance access negotiation system, comprehensively considers factors such as clinical needs and the ability to withstand medical insurance funds, and incorporates more eligible rare medical drugs in accordance with procedures into the medical insurance and drug directory.Further improve the level of rare diseases.